Addinex Technologies

Addinex Technologies, Inc., founded in 2017, is a healthcare technology company addressing the opioid crisis and prescription drug misuse. The company was co-founded by Jay Schiff, who serves as CEO, and Stanislav Roslyakov, the CTO. Schiff is a Wall Street veteran with a background in investing in small- and mid-sized businesses, holding a BA in Economics from Cornell University and an MBA in Finance from NYU. Roslyakov is an engineer with experience in mechanical, electrical, and software engineering, holding both BS and MS degrees from NYU.

The company has developed a patented, low-cost medication dispensing system designed to prevent misuse, addiction, and overdose. The business targets the healthcare market, specifically clinicians, doctors, and patients, to counter issues like overprescribing, overuse, and the retention of excess pills. Addinex's system combines a physical, non-electronic dispenser with a digital application available on mobile and web. This integrated platform controls access to medication based on the prescribed schedule through dynamically generated passcodes, which patients must request via the app to get their next dose. This mechanism prevents patients from accessing pills before the designated time interval has passed.

The system provides several layers of protection and support. It offers real-time education to patients about side effects and addiction risks each time they take a dose. The connected app monitors treatment progression, pain levels, and can alert the patient, their doctor, and a designated caregiver of any abnormal usage patterns. A significant feature is the facilitation of easy and proper disposal of unused medication. The system includes a DEA-approved, prepaid mailer to return the dispenser with any excess pills, directly addressing the problem of leftover drugs being diverted or misused. Clinical study results from a partnership with Columbia University Irving Medical Center demonstrated a high rate of excess medication disposal (84%) and a significant reduction in opioid use compared to prescriptions. Addinex has received grants from the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) to further develop its technology for various applications, including for buprenorphine treatment in patients with opioid use disorder and for use in decentralized clinical trials.

Keywords: medication misuse prevention, opioid crisis, prescription drug safety, smart pill dispenser, medication adherence, digital health, HealthTech, controlled substance dispensing, overdose prevention, patient monitoring, medication disposal, clinical trial medication management, buprenorphine treatment, telehealth, medical device, Jay Schiff, Stanislav Roslyakov, password-protected dosage, real-time patient education, addiction treatment technology